TACROLIMUS

Myelofibrosis

Stanford UniversitySmall moleculePhase 3Active

B

60/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 53/ 100
Competitive Position: 73/ 100

Competitive context

48 Active assets in the Myelofibrosis cohort.

Asset / Sponsor	Phase	Rating
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center	Phase 2	BB
Busulphan City of Hope Medical Center	Phase 2	B
Cyclophosphamide City of Hope Medical Center	Phase 3	B
CYCLOSPORIN A City of Hope Medical Center	Phase 2	B
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center	Phase 2/3	B

View all 50 →

Same molecule, other indications

TACROLIMUS is also rated in:

disease related to transplantationDormant

BBB

Indicative ·

79 / 100

disease related to solid organ transplantationDormant

BBB

Indicative ·

76 / 100

beta-thalassemia majorDormant

BBB

Indicative ·

75 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.